Evaluation of RF300 for Leukoreduction of Red Blood Cells.
- Author:
So Yong KWON
1
;
Nam Sun CHO
;
Sun Nyeo SONG
;
Ju Yeon LEE
;
A Hyun LIM
;
Hyeon Mi LEE
;
Yeong Cheon JI
;
Chang Sik SEO
;
Yun Hui PARK
Author Information
1. Blood Service Headquarters, Korean Red Cross, Seoul, Korea. bs510@redcross.or.kr
- Publication Type:Original Article
- Keywords:
RF300;
Leukoreduction;
Red blood cells
- MeSH:
Blood Group Incompatibility;
Collodion;
Erythrocytes;
Filtration;
Hemolysis;
Leukocyte Count;
Leukocytes;
Tokyo;
Washington
- From:Korean Journal of Blood Transfusion
2012;23(1):13-19
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Use of universal leukoreduction for prevention of leukocyte associated transfusion reactions is common practice in many countries. This study was conducted in order to evaluate the performance of a newly developed leukoreduction filter for red blood cells (RBCs), the RF300 (Kolon Industries, Inc, Gumi, Korea). METHODS: Filtration time, RBC recovery, residual leukocyte count, and leukocyte removal rate were evaluated. To assess the quality of RBCs after filtration, percent hemolysis was monitored for a period of 21 days. Performance of the RF300 (N=78) was compared with that of the Bio-R O2 plus (Fresenius, Hamburg, Germany), the Pall Purecell RC (Pall Co., Washington, USA), and the Sepacell R-500N (Asahi, Tokyo, Japan). RESULTS: The shortest filtration time was observed using the RF300 (P<0.05). Using the RF300, recovery of RBC was 96.5%, which was higher than that of two filters (P<0.05). Mean residual leukocyte count was 0.26x10(6)/unit, with a leukocyte removal rate of 3 log. Using the RF300, mean percent hemolysis was 0.32% at day 21, which was comparable with that of two filters, but lower than that of one filter (P<0.05). CONCLUSION: The RF300 meets all established quality requirements for conduct of safe and effective leukoreduction of RBCs.
